Sutimlimab-jome (Enjaymo)
Optional dilutionFull monograph review pending
U.S. label preparation
Enjaymo · Optional dilution
- Preparation
- The label permits undiluted infusion or dilution to a total of 500 mL using 0.9% sodium chloride.
- Administration and handling
- Use Table 1 for undiluted infusion or Table 2 for diluted infusion. Rates depend on weight and cardiopulmonary status.
Product and source details
Recordati Rare Diseases, Inc. · BLA761164
Product NDC: 55292-820
SPL effective 2026-03-02 | SPL version 4. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.